VaccinesNews.net

Vaccines Xagena

It has been assessed the risk of maternal, fetal, and neonatal outcomes associated with the administration of an MF59 adjuvanted A/H1N1 vaccine during pregnancy. The trial was conducted in singleto ...


The objective of a study was to measure the effectiveness of the quadrivalent human papillomavirus ( HPV ) vaccine against cervical abnormalities four years after implementation of a nationally funded ...


Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both t ...


In low-income countries, live measles vaccine reduces mortality from causes other than measles infection. Such nonspecific effects of vaccines might also be important for the health of children in hig ...


In March 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine ( PCV10 ), which was licensed based on non-inferiority of immunological correlates of protection compared with the seven- ...


The TGA ( Therapeutic Goods Administration ) has been undertaking enhanced monitoring of the meningococcal B vaccine, Bexsero. Bexsero is the first vaccine in Australia intended to prevent invasive ...


Health professionals are reminded that, to minimise the risk of fever and febrile convulsion, measles, mumps, rubella, varicella vaccine should not be administered as the first dose of measles-contain ...


Present combination antiretroviral therapy ( cART ) alone does not cure HIV infection and requires lifelong drug treatment. The potential role of HIV therapeutic vaccines as part of an HIV cure is und ...


International postlicensure studies have identified an increased risk of intussusception after vaccination with the second-generation rotavirus vaccines RotaTeq ( RV5, a pentavalent vaccine ) and Rota ...


Rates of varicella have decreased substantially in countries implementing routine varicella vaccination. Immunisation is possible with monovalent varicella vaccine or a combined measles-mumps-rubella- ...


Merck & Co has announced that in the pivotal phase III efficacy study, its investigational 9-valent HPV vaccine ( V503 ) prevented approximately 97% of cervical, vaginal and vulvar pre-cancers cau ...


Pfizer has announced that the Community-Acquired Pneumonia Immunization Trial in Adults ( CAPiTA ), the landmark study of approximately 85,000 subjects evaluating the efficacy of Prevenar 13 ( pneumoc ...


The possible risk of Guillain-Barré syndrome from influenza vaccines remains a potential obstacle to achieving high vaccination coverage. However, influenza infection might also be associated with Gui ...


Enterovirus 71 ( EV71 ) outbreaks are a socioeconomic burden, especially in the western Pacific region. Results of phase 1 clinical trials suggest an EV71 vaccine has a clinically acceptable safety pr ...


BCG vaccination provides incomplete protection against tuberculosis in infants. A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A ( MVA85A ), was designed to enhance the protective ...


A vaccine for enterovirus 71 ( EV71 ) is needed to address the high burden of disease associated with infection. Researchers have assessed the efficacy, safety, immunogenicity, antibody persistence, a ...


A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 ( HIV-1 ) infection is a global priority.Researchers have tested the efficacy of a DNA prime-recombinant adenovir ...


The influenza A(H1N1) 2009 monovalent vaccination programme was the largest mass vaccination initiative in recent US history. Commensurate with the size and scope of the vaccination programme, a proje ...


The candidate malaria vaccine RTS,S/AS01E has entered phase 3 trials, but data on long-term outcomes are limited.For 4 years, researchers followed children who had been randomly assigned, at 5 to 17 m ...


During the 2009 influenza A (H1N1) pandemic, pregnant women were at risk for severe influenza illness. This concern was complicated by questions about vaccine safety in pregnant women that were raised ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati